Bausch + Lomb (BLCO) | Financial Analysis & Statements
Bausch + Lomb Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
1.4B
Gross Profit
872.0M
62.06%
Operating Income
158.0M
11.25%
Net Income
-58.0M
-4.13%
EPS (Diluted)
$-0.16
Balance Sheet Metrics
Total Assets
14.0B
Total Liabilities
7.5B
Shareholders Equity
6.5B
Debt to Equity
1.15
Cash Flow Metrics
Operating Cash Flow
91.0M
Free Cash Flow
60.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Bausch + Lomb Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.1B | 4.8B | 4.1B | 3.8B | 3.8B |
| Cost of Goods Sold | 2.0B | 1.9B | 1.6B | 1.5B | 1.5B |
| Gross Profit | 3.1B | 2.9B | 2.5B | 2.2B | 2.3B |
| Gross Margin % | 59.8% | 60.9% | 60.4% | 59.7% | 61.0% |
| Operating Expenses | |||||
| Research & Development | 371.0M | 343.0M | 324.0M | 308.0M | 276.0M |
| Selling, General & Administrative | 2.2B | 2.1B | 1.7B | 1.5B | 1.4B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 2.6B | 2.4B | 2.1B | 1.8B | 1.7B |
| Operating Income | 188.0M | 206.0M | 204.0M | 219.0M | 341.0M |
| Operating Margin % | 3.7% | 4.3% | 4.9% | 5.8% | 9.1% |
| Non-Operating Items | |||||
| Interest Income | 12.0M | 15.0M | 15.0M | 6.0M | 0 |
| Interest Expense | 421.0M | 399.0M | 283.0M | 146.0M | 0 |
| Other Non-Operating Income | -96.0M | -56.0M | -102.0M | -6.0M | -23.0M |
| Pre-tax Income | -317.0M | -234.0M | -166.0M | 73.0M | 318.0M |
| Income Tax | 35.0M | 71.0M | 82.0M | 58.0M | 125.0M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 79.5% | 39.3% |
| Net Income | -352.0M | -305.0M | -248.0M | 15.0M | 193.0M |
| Net Margin % | -6.9% | -6.4% | -6.0% | 0.4% | 5.1% |
| Key Metrics | |||||
| EBITDA | 621.0M | 657.0M | 601.0M | 604.0M | 757.0M |
| EPS (Basic) | - | $-0.90 | $-0.74 | $0.02 | $0.52 |
| EPS (Diluted) | - | $-0.90 | $-0.74 | $0.02 | $0.52 |
| Basic Shares Outstanding | - | 351800000 | 350500000 | 350000000 | 350000000 |
| Diluted Shares Outstanding | - | 351800000 | 350500000 | 350000000 | 350000000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Bausch + Lomb Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 383.0M | 305.0M | 331.0M | 354.0M | 174.0M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 1.2B | 1.0B | 839.0M | 724.0M | 721.0M |
| Inventory | 976.0M | 1.0B | 1.0B | 628.0M | 572.0M |
| Other Current Assets | 383.0M | 410.0M | 541.0M | 405.0M | 165.0M |
| Total Current Assets | 3.0B | 2.8B | 2.7B | 2.1B | 1.6B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 0 | 335.0M | 232.0M |
| Goodwill | 12.8B | 12.5B | 12.7B | 11.1B | 11.4B |
| Intangible Assets | 3.3B | 3.5B | 3.6B | 2.1B | 2.3B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.2B | 1.2B | 1.1B | 1.1B | 1.1B |
| Total Non-Current Assets | 11.0B | 10.7B | 10.7B | 9.0B | 9.2B |
| Total Assets | 14.0B | 13.5B | 13.4B | 11.1B | 10.8B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 388.0M | 389.0M | 522.0M | 370.0M | 239.0M |
| Short-term Debt | 39.0M | 40.0M | 30.0M | 25.0M | 28.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 487.0M | 403.0M | 400.0M | 342.0M | 316.0M |
| Total Current Liabilities | 1.9B | 1.7B | 1.6B | 1.3B | 1.1B |
| Non-Current Liabilities | |||||
| Long-term Debt | 5.0B | 4.7B | 4.5B | 2.4B | - |
| Deferred Tax Liabilities | 19.0M | 13.0M | 14.0M | 7.0M | 24.0M |
| Other Non-Current Liabilities | 521.0M | 430.0M | 397.0M | 329.0M | 298.0M |
| Total Non-Current Liabilities | 5.6B | 5.2B | 4.9B | 2.7B | 322.0M |
| Total Liabilities | 7.5B | 6.9B | 6.5B | 4.0B | 1.4B |
| Equity | |||||
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -931.0M | -571.0M | -254.0M | 6.0M | 0 |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 6.5B | 6.5B | 6.9B | 7.1B | 9.4B |
| Key Metrics | |||||
| Total Debt | 5.1B | 4.8B | 4.6B | 2.4B | 28.0M |
| Working Capital | 1.1B | 1.0B | 1.2B | 841.0M | 536.0M |
Balance Sheet Composition
Bausch + Lomb Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -352.0M | -305.0M | -248.0M | 15.0M | 193.0M |
| Depreciation & Amortization | 421.0M | 436.0M | 382.0M | 379.0M | 415.0M |
| Stock-Based Compensation | 149.0M | 92.0M | 74.0M | 62.0M | 62.0M |
| Working Capital Changes | -2.0M | -248.0M | -140.0M | -12.0M | 41.0M |
| Operating Cash Flow | 240.0M | 48.0M | 110.0M | 339.0M | 825.0M |
| Investing Activities | |||||
| Capital Expenditures | -349.0M | -291.0M | -181.0M | -175.0M | -193.0M |
| Acquisitions | -122.0M | -138.0M | -1.9B | -45.0M | -16.0M |
| Investment Purchases | -11.0M | -12.0M | -17.0M | -17.0M | -19.0M |
| Investment Sales | 8.0M | 14.0M | 16.0M | 22.0M | 14.0M |
| Investing Cash Flow | -467.0M | -425.0M | -2.1B | -215.0M | -214.0M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 3.4B | 631.0M | 2.3B | 2.5B | 28.0M |
| Debt Repayment | -3.1B | -430.0M | -161.0M | -13.0M | 0 |
| Financing Cash Flow | 225.0M | 178.0M | 2.1B | 81.0M | -712.0M |
| Free Cash Flow | -66.0M | -59.0M | -198.0M | 170.0M | 680.0M |
| Net Change in Cash | -2.0M | -199.0M | 66.0M | 205.0M | -101.0M |
Cash Flow Trend
Bausch + Lomb Key Financial Ratios
Valuation Ratios
Forward P/E
15.00
Price to Book
0.87
Price to Sales
1.11
PEG Ratio
15.00
Profitability Ratios
Profit Margin
-7.06%
Operating Margin
11.25%
Return on Equity
-5.39%
Return on Assets
0.86%
Financial Health
Current Ratio
1.55
Debt to Equity
80.46
Beta
0.65
Per Share Data
EPS (TTM)
$-1.02
Book Value per Share
$18.20
Revenue per Share
$14.42
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BLCO | 5.6B | - | 0.87 | -5.39% | -7.06% | 80.46 |
| Intuitive Surgical | 170.1B | 54.97 | 8.99 | 16.69% | 28.38% | 0.95 |
| Becton, Dickinson | 56.1B | 25.40 | 1.75 | 6.96% | 8.01% | 77.28 |
| Baxter International | 9.4B | 86.31 | 1.54 | -13.71% | -8.51% | 160.28 |
| AptarGroup | 8.0B | 21.10 | 2.99 | 15.10% | 10.40% | 57.10 |
| Repligen | 7.5B | 154.30 | 3.55 | 2.40% | 6.62% | 32.76 |
Financial data is updated regularly. All figures are in the company's reporting currency.






